Concepedia

David Margolin

DM

45

Publications

5.2K

Citations

27

H-Index

1982

Active since

Affiliations

University of Cambridge(Current)

Sanofi (United States)

Cleveland Clinic

Charles University

Beth Israel Deaconess Medical Center

David Margolin is an author at University of Cambridge specializing in medicine, neuroscience, and neuropharmacology.

Top concepts

Publications per year

1982–2022

45

Publications

45

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

, , +8

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

, , +4

Alemtuzumab CARE-MS II 5-year follow-up

Alasdair Coles, Jeffrey Cohen, Edward Fox et al. · Neurology · 2017 · 273 citations · Full text

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

Alasdair Coles, Edward Fox, Anton Vladić et al. · Neurology · 2012 · 260 citations

Ataxia, Dementia, and Hypogonadotropism Caused by Disordered Ubiquitination

David Margolin, Maria Kousi, Yee-Ming Chan et al. · New England Journal of Medicine · 2013 · 229 citations · Full text

Rows per page

1–5 of 45